Recent developments in spinal cord imaging
ECTRIMS Online Library. Ciccarelli O. Oct 12, 2018; 232019; 266
Olga Ciccarelli
Olga Ciccarelli
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Discussion Forum (0)
Rate & Comment (0)

Abstract: 266

Type: Scientific Session

Abstract Category: N/A

Spinal cord pathology is frequent in MS and clinically relevant. Recent developments in advanced imaging of the spinal cord have allowed us to obtain insights into the structural, metabolic and functional changes in-vivo in patients with MS. A recent study using neurite orientation dispersion and density imaging (NODDI) has shown that neurite density index is lower in the spinal cord of MS patients than healthy controls and is associated with clinical disability. A pilot study with sodium MRI has shown increased total sodium concentration in the cervical cord of MS patients when compared to healthy controls, which suggests an increase in intra- and extra-cellular sodium, associated with neurodegeneration. Functional connectivity in the spinal cord of patients with MS has been examined for the first time using resting-state functional MRI at 7 T: spinal cord functional networks appear to be intact in relapsing-remitting MS, but lesions are associated with focal abnormalities. Spinal cord lesion topography has been assessed in a large cohort of patients with MS using registration-based techniques and voxel-based lesion probability mapping, and this has shown a predominance of lesions in the upper cord and dorsal column, confirming histopathological work. Spinal cord area is used as outcome measure in clinical trials only occasionally; changes over time in spinal cord cross-sectional area are calculated by repeating the measurements indipendently at each time point. More recently, registration-based techniques for spinal cord atrophy, which are similar to the techniques used for brain atrophy calculation, have been developed and tested in longitudinal cohorts and clinical trials. Spinal cord atrophy is mostly driven by grey matter atrophy, which is more pronounced in progressive compared to relapsing-remitting MS, and correlates with disability more strongly than total cord area. Thus, spinal cord imaging has the potential of providing parameters that can be used to improve our understanding of the mechanisms of damage in MS, as surrogate outcomes in clinical trials and for monitoring therapeutic response in MS.
Disclosure: OC is a consultant for Novartis, Teva, Roche, Biogen and Merck.

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.

Save Settings